CYCN · Cyclerion Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company's expectation to generate negative operating cash flows in the future and the need for additional funding to support its planned operations, raise substantial doubt regarding the Company's ability to continue as a going concern. Management's plans to alleviate the conditions that raise substantial doubt include reduced spending, and the pursuit of additional capital. Management has concluded the likelihood that its plan to successfully obtain sufficient funding, or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 4, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $1.99M | $2.07M | $2M | $0 | $297K | $3.94M | $2.3M | $4.51M | — | |
| $1.65M | $959K | $286K | $1.52M | $5.98M | $37.64M | $56.41M | $95.14M | $87.72M | |
| $7.13M | $6.09M | $5.34M | $8.13M | $12.86M | $20.62M | $28.82M | $34.4M | $27.54M | |
| — | — | — | $0 | $65K | $472K | $2.3M | $2.7M | $1.53M | |
| — | — | — | -$565K | -$1.33M | — | — | — | — | |
| $1.77M | $7.05M | $5.63M | $12.95M | $18.84M | $59.14M | $83.56M | $129.54M | $115.25M | |
| -$6.82M | -$4.97M | -$3.63M | -$12.95M | -$18.54M | -$55.2M | -$81.27M | -$125.04M | -$115.25M | |
| — | -239.78% | -181.4% | — | -6242.42% | -1400.18% | -3539.42% | -2774.28% | — | |
| — | — | — | -$12.95M | -$18.48M | -$54.72M | -$78.97M | -$122.34M | -$113.72M | |
| $117K | $1.45M | $571K | $358K | $294K | -$16K | $588K | — | — | |
| — | -$3.53M | -$3.06M | -$5.26M | -$44.08M | -$51.65M | -$122.41M | -$122.41M | -$115.25M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$6.71M | -$3.53M | -$3.06M | -$5.26M | -$44.08M | -$51.65M | -$77.8M | -$123.01M | -$115.25M | |
| — | -170.11% | -152.85% | — | -14841.08% | -1310.17% | -3388.59% | -2729.27% | — | |
| USD/shares | — | -$1.11 | -$1.21 | -$2.25 | -$20.28 | -$26.40 | — | — | — |
| USD/shares | — | -$1.11 | -$1.21 | -$2.25 | -$20.28 | -$26.40 | — | — | — |
| shares | — | 3.18M | 2.52M | 2.34M | 2.17M | 1.96M | 1.52M | 1.37M | 1369 |
| shares | — | 3.18M | 2.52M | 2.34M | 2.17M | 1.96M | 1.52M | 1.37M | 1369 |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 238 similar-size Biotechnology companies (of 534 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| License Agreement | $1,000,000 | $1,750,000 | $0 |
| Purchase Agreement | $800,000 | $0 | — |
| Option Agreement | $274,000 | $250,000 | — |
| License | — | — | $0 |